LDLR and familial hypercholesterolemia: These findings establish PT as a promising nutraceutical candidate for managing hypercholesterolemia, particularly in cases of statin resistance or intolerance, through its novel epigenetic control of the p300–PCSK9–LDLR axis [30, 48].